Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
MM&M6d
Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
Pharm Exec5d
Novartis Strikes Deal to Acquire Anthos Therapeutics
Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...
Novartis: Strong Execution With A P/E Discount
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
PMLiVE6d
Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition
Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...
The Pharma Letter6d
Novartis to boost cardio pipeline with Anthos Therapeutics buy
Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...